



HAL
open science

Stromal fibroblasts present in breast carcinomas promote tumor growth and angiogenesis through adrenomedullin secretion

Zohra Benyahia, Nadège Dussault, Mylène Cayol, Romain Sigaud, Caroline Berenguer-Daizé, Christine Delfino, Asma Tounsi, Stéphane Garcia, Pierre-Marie Martin, Kamel Mabrouk, et al.

► **To cite this version:**

Zohra Benyahia, Nadège Dussault, Mylène Cayol, Romain Sigaud, Caroline Berenguer-Daizé, et al.. Stromal fibroblasts present in breast carcinomas promote tumor growth and angiogenesis through adrenomedullin secretion. *Oncotarget*, 2017, 8 (9), 10.18632/oncotarget.14999 . hal-01699152

HAL Id: hal-01699152

<https://amu.hal.science/hal-01699152>

Submitted on 2 Feb 2018

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Stromal fibroblasts present in breast carcinomas promote tumor growth and angiogenesis through adrenomedullin secretion

Zohra Benyahia¹, Nadège Dussault¹, Mylène Cayol¹, Romain Sigaud¹, Caroline Berenguer-Daizé¹, Christine Delfino¹, Asma Tounsi¹, Stéphane Garcia², Pierre-Marie Martin¹, Kamel Mabrouk³, L'Houcine Ouafik^{1,4}

¹Aix Marseille Univ, The Institut National pour la Recherche Médicale, Centre de Recherche en Oncologie et Oncopharmacologie, UMR 911, 13005, Marseille, France

²Assistance Publique Hôpitaux de Marseille, Laboratoire d'Anatomie Pathologique, 13015, Marseille, France

³Aix Marseille Univ, CNRS, ICR, UMR 7273 CROPS, 13397, Marseille, France

⁴Assistance Publique Hôpitaux de Marseille, Service de Transfert d'Oncologie Biologique, 13015, Marseille, France

Correspondence to: L'Houcine Ouafik **email:** lhoucine.ouafik@univ-amu.fr

Keywords: adrenomedullin, breast cancer, myofibroblasts, invasion, tumor growth

Received: July 20, 2016

Accepted: January 03, 2017

Published: February 02, 2017

ABSTRACT

Tumor- or cancer-associated fibroblasts (TAFs or CAFs) are active players in tumorigenesis and exhibit distinct angiogenic and tumorigenic properties. Adrenomedullin (AM), a multifunctional peptide plays an important role in angiogenesis and tumor growth through its receptors calcitonin receptor-like receptor/receptor activity modifying protein-2 and -3 (CLR/RAMP2 and CLR/RAMP3). We show that AM and AM receptors mRNAs are highly expressed in CAFs prepared from invasive breast carcinoma when compared to normal fibroblasts. Immunostaining demonstrates the presence of immunoreactive AM and AM receptors in the CAFs (n = 9). The proliferation of CAFs is decreased by anti-AM antibody (αAM) and anti-AM receptors antibody (αAMR) treatment, suggesting that AM may function as a potent autocrine/paracrine growth factor. Systemic administration of αAMR reduced neovascularization of *in vivo* Matrigel plugs containing CAFs as demonstrated by reduced numbers of the vessel structures, suggesting that AM is one of the CAFs-derived factors responsible for endothelial cell-like and pericytes recruitment to built a neovascularization. We show that MCF-7 admixed with CAFs generated tumors of greater volume significantly different from the MCF-7 xenografts in nude mice due in part to the induced angiogenesis. αAMR and AM₂₂₋₅₂ therapies significantly suppressed the growth of CAFs/MCF-7 tumors. Histological examination of tumors treated with AM₂₂₋₅₂ and αAMR showed evidence of disruption of tumor vasculature with depletion of vascular endothelial cells, induced apoptosis and decrease of tumor cell proliferation. Our findings highlight the importance of CAFs-derived AM pathway in growth of breast carcinoma and in neovascularization by supplying and amplifying signals that are essential for pathologic angiogenesis.

INTRODUCTION

Although tumorigenesis has classically been viewed as a largely cell-autonomous process involving genetically transformed cancer cells, the importance of stromal cell types populating the neoplastic microenvironment is now well accepted [1, 2]. The contribution of the stromal microenvironment to the development of a wide variety

of tumors has been supported by the use of experimental mouse models of cancer pathogenesis [3] and by clinical evidence [4, 5]. The accumulated evidence indicates that tumor cells actively recruit stromal cells, such as inflammatory cells, vascular cells, and fibroblasts [6, 7], into the tumor, and that this recruitment is essential for the generation of a microenvironment that actively fosters tumor growth.

The reactive tumor stroma is characterized by expansion and activation of the fibroblast population, excessive production of extracellular matrix (ECM), and persistent inflammation [7]. The cancer-associated fibroblasts (CAFs) are phenotypically and functionally distinguishable from their normal counterparts in their increased rate of proliferation and differential expression of extracellular matrix (ECM) components and growth factors [7, 8]. Several studies have demonstrated that normal fibroblasts have a role in maintaining epithelial homeostasis by suppressing proliferation and oncogenic potential of adjacent epithelia [3, 9]. However, following neoplastic transformation of epithelia, CAFs have been shown to promote tumor growth by inducing angiogenesis, recruiting bone marrow-derived endothelial progenitor cells, and remodeling the ECM [6, 10, 11]. Interestingly, CAFs can even mediate resistance to antiangiogenic therapy [12]. Some CAFs are related to myofibroblasts, an activated form of fibroblast that plays an important role in wound healing and is characterized by expression of α -SMA. Not all CAFs, however, express α -SMA. Increasingly, fibroblasts in tumor tissues are being recognized as a diverse population of myofibroblastic cells intermixed with other fibroblastic cells that do not express α -SMA but may nevertheless be tumor promoting [13, 14].

Characterization of the expression profiles of CAFs has identified this cell type as an important producer of chemokines and growth factors [10, 11]. Adrenomedullin (AM), one such factor, belongs to a family of peptides that includes calcitonin, α - and β -calcitonin gene related peptide (CGRP) and amylin. It acts through the G protein-coupled receptor calcitonin receptor-like receptor (CLR), with specificity for AM being conferred by the receptor activity modifying protein 2 (RAMP2) and 3 (RAMP3) [15]. The ability of CLR/RAMP2 and CLR/RAMP3 to respond with high affinity to AM implies the existence of two molecularly distinct AM receptors referred to as AMR₁ and AMR₂ receptors [16]. Many functions have been ascribed to AM. It has been shown to be a multifunctional peptide with properties ranging from inducing vasorelaxation to acting as a regulator of cellular growth [17, 18]. AM is widely expressed in a variety of tumor types [19] and was shown to be mitogenic for many human cancer cell lines *in vitro* [20]. Several *in vivo* studies have shown a regression of tumor growth upon the treatment with neutralizing AM antibodies [21–23], AM receptor antagonist [24, 25], or AM receptor interference [26].

It is important to point out that AM from sources other than the tumor cells themselves (i.e., paracrine sources, such as fibroblasts, blood vessels, immune cells, that surround the tumor bed) could influence the behavior of tumor cells. We are gradually beginning to understand the importance of non-tumor cells in the development of cancer [2], but more attention is needed in understanding how it relates to AM production. Accumulating studies

suggest a new role for AM as a cross-talk molecule that integrates tumor and tumor-infiltrating mast cells [27], tumor-infiltrating macrophages [28], or endothelial cells of the tumor [29] communication, underlying a promotion mechanism to facilitate angiogenesis and tumor growth. These results provide a new insight into the dynamic nature of these tumor-infiltrating cells during the tumor growth and support that AM can function as a key factor in this process. Many reports suggest that fibroblasts in tumor masses possess biological characteristics distinct from those of normal fibroblasts [10, 11]. In this study, characterization of human breast carcinomas CAFs led to the identification of AM as a novel CAF-derived tumor stimulatory factor that played a determinant role in human breast cancer, especially with respect to growth, invasion and angiogenesis.

RESULTS

Isolation of primary fibroblastic population from invasive human breast cancers

We extracted fibroblasts from human invasive mammary ductal carcinomas (n = 9) obtained from mastectomies. The tumor masses were dissociated, and various cell types were separated to obtain populations of carcinoma-associated fibroblasts (CAFs). We then verified the purity of the fibroblasts populations by immunostaining. These fibroblast populations strongly expressed fibroblastic markers such as vimentin (Figure 1A, a), PDGFR α (Figure 1A, b), and fibroblast surface protein-1 (FSP-1) (Figure 1A, c), whereas these cells were negative for cytokeratin (Figure 1A, e). Fibroblasts can be misidentified as macrophages because both cell types share antigens that are associated with antibodies targeting the monocyte/macrophage lineage. To determine whether macrophages cells do not contaminate the isolated cells prepared from breast cancer tissues, we used immunofluorescence to investigate the expression of various macrophage surface markers including F4/80, CD68 and CD163 [30]. Co-expression of CD68 and CD163, is a marker for the M2 anti-inflammatory macrophage phenotype [30]. As illustrated in Figure 1B, immunofluorescence revealed a barely detectable immunostaining of CD68 in CAFs (Figure 1B, d) and NHDFs (Figure 1B, g) meanwhile no expression can be detected for CD163 and F4/80 markers in CAFs (Figures 1B, e and f) and in NHDFs (Figures 1B, h and i), ruling out that the cells prepared from breast cancer tissue are not macrophages. The RAW264.7 cells, a partially differentiated macrophage-like monocytic cell line [31], was used as positive control, which expresses strongly CD68 (Figure 1B, a) and F4/80 (Figure 1B, c) markers with a moderate expression of CD163 marker (Figure 1B, b). In agreement with the present data, previous studies reported that fibroblasts isolated from normal skin, normal




Figure 1: Fibroblastic properties of primary human fibroblasts prepared from human breast cancer tissues. **A.** Immunofluorescent staining of cultured CAFs (**a, b, c, d,** and **e**) and MCF-7 cells (**f**) using anti-vimentin (**a**), anti-PDGFR α (**b**), anti-FSP1 (**c**), anti-cytokeratin 18 (**e** and **f**) antibodies. Secondary antibody anti-rabbit was used as control (**d**). Scale bar, 50 μ m. **B.** Immunocytochemical staining with CD68, CD163, and F4/80 antibodies. Fluorescent microscopy images indicating expressions of CD68, CD163, and F4/80 in macrophage/monocyte RAW264.7 cells (**a, b,** and **c**). In CAFs and NHDFs, barely detectable expression is seen for CD68 (**d, g**); meanwhile no expression can be detected for CD163 (**e, h**) and F4/80 (**f, i**).

breast, and breast tumor tissue clearly expressed CD68 protein at levels comparable to macrophages [32, 33].

We also found that no more than 0.1% of the cells in each fibroblast population were positive for CD31, CD45, CD11b and CD268 (data not shown). Taken together, these observations indicate that these fibroblast populations were prepared with minimal contamination by epithelial, endothelial, or hematopoietic cells, such as leukocytes and erythrocytes.

Characterization of CAFs as activated fibroblasts (myofibroblasts)

Expression of α -smooth muscle actin (α -SMA) is a defining characteristic of myofibroblasts [34]. An increased proportion of α -SMA-positive myofibroblasts was seen in three isolated CAF populations when compared to normal human dermal fibroblasts (NHDFs) (Figures 2A, 2B). The increased α -SMA expression was largely maintained in the initially characterized CAF cells for up to nine population doublings *in vitro* (Figure 2B), indicating that isolated CAFs contain a high proportion of myofibroblasts. These results confirmed that the CAFs possessed the properties of myofibroblasts and maintained these traits without the continued presence of carcinoma cells.

Expression of AM, CLR, RAMP2, and RAMP3 in CAFs

CAFs promote tumor formation in human breast cancers [11]. CAFs are a source of growth factors, like

hepatocyte growth factor, EGF, TGF- β , and chemokines, such as CCL5 and CCL12, which are known to exert protumorigenic and prometastatic actions [35, 36]. We hypothesized that AM is one of the CAF-derived factors that might be involved in the CAFs-induced tumor formation and angiogenesis. We therefore quantified expression levels of AM mRNA in the various stromal fibroblast populations. Total RNA from NHDFs (n = 3) and CAFs (n = 9) was prepared to assess the steady-state levels of AM, CLR, RAMP2, and RAMP3 mRNA transcripts. The individual patterns of expression of AM mRNA are presented in Figure 3A. Quantification of the AM mRNA transcripts revealed 4- to 24- fold higher levels of AM mRNA in CAFs when compared to NHDFs. Among the CAFs populations, the individual pattern of expression for AM, CLR, RAMP2, and RAMP3 mRNAs was highly variable (Figure 3A). Interestingly, SDF1 mRNA demonstrated higher expression in CAFs when compared to NHDFs (Supplementary Figure 1). The increase of SDF1 expression in CAFs is in agreement with the previously reported study [11]. A clear variability of expression of AM and SDF1 mRNAs can be observed in individual CAF (Supplementary Figure 1). Omission of reverse transcriptase eliminated all signals, thus suggesting that our results were not attributable to contaminating genomic DNA.

The presence and cellular localization of AM, CLR, RAMP2, and RAMP3 in CAFs was analyzed using immunofluorescence. Representative images are shown in Figure 3B; in the images CAFs have been immunostained for AM, CLR, RAMP2 and RAMP3. Positive staining was completely abolished by pre-absorption of the antibody with 50 μ M synthetic peptide (not shown).





Figure 2: CAFs exhibit characteristic of “Myofibroblasts”. A. NHDFs (a) and CAF1, 2 and 3 cells (b, c and d) were cultured in DMEM/F12 with 10% FBS and immunostained with anti- α -SMA antibody. Scale bar, 50 μ m. B. α -SMA-positive cell counts as a fraction of total cell numbers (> 100 counted cells) were evaluated in ten independent fields from four different wells of each fibroblast type under a fluorescence microscope ($P < 0.05$).

Expression of immunoreactive AM by CAFs and NHDFs

In addition, we performed an ELISA assay on the cell extracts and medium conditioned by each CAF population as well as NHDFs. This assay indicated elevated levels of immunoreactive AM (ir-AM) in the

medium conditioned by CAF1 (175 ± 10 pg/ml/24h/ 10^5 cells), CAF2 (129 ± 8 pg/ml/24h/ 10^5 cells), and CAF3 (190 ± 13 pg/ml/24h/ 10^5 cells) cells when compared to the levels produced by the NHDFs (32 ± 5 pg/ml/24h/ 10^5 cells). To determine the intracellular ir-AM levels in CAFs and NHDFs, peptide levels were measured in cell lysates. Intracellular ir-AM accumulated was in CAF1 (152 ± 8



B




Figure 3: Expression of AM and its receptors in CAFs and NHDFs. A. expression of AM, CLR, RAMP2, and RAMP3 mRNAs in NHDFs and CAFs. Total RNA ($1 \mu\text{g}$, DNA-free) prepared from NHDFs ($n = 3$) and CAFs ($n = 9$) was transcribed into cDNA and subjected to real-time quantitative reverse transcriptase-polymerase chain reaction for the estimation of the relative ratios of AM, CLR, RAMP2, and RAMP3 mRNAs to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA. Each bar depicts the mean \pm standard error of the mean of the two independent experiments from two independent preparations of total RNA from NHDFs and CAFs. **B.** immunofluorescence for AM, CLR, RAMP2, and RAMP3 in CAFs where strong cytoplasmic staining is observed.

pg/mg protein), CAF2 (137 ± 10 pg/mg protein), CAF3 (349 ± 15 pg/mg protein), and NHDFs (47 ± 5 pg/mg protein) and shows a clear increase of ir-AM content in CAFs when compared to NHDFs. These data demonstrate that ir-AM is synthesized and actively secreted by CAFs suggesting that it may function as a chemokine and/or growth factor to participate in cross talk between components of tumor microenvironment *in vivo* and/or chemoattractant of AMR⁺ circulating cells.

AM mediate the phosphorylation of MAPK and AM blockade inhibits CAFs proliferation

ERK and serine/threonine protein kinase (Akt) regulate cell proliferation, and both of these signaling pathways function downstream of the AM/cAMP pathway [23, 37]. Therefore, we examined the kinetics through which AM enhanced MAPK signaling. Treatment of CAFs with AM led to prolonged phosphorylation of ERK1/2 that was initially observed after 5 min of treatment and continued to increase through 20 min of treatment (Figure 4A). This increase in signaling correlated with sustained phosphorylation of ERK1/2 MAPK in CAFs (Figure 4A). Inhibition of MEK, an immediate upstream activator of ERK1/2, with U0126 (10 μ M for 30 min) prevented AM-mediated activation of ERK1/2 (Figure 4A). Pre-incubation of CAFs with α AMRs prevented the stimulatory effect of AM on pERK1/2 and also decreased strongly the pERK1/2 levels observed in control cells suggesting that the endogenous AM secreted by CAFs might be involved by autocrine/paracrine loop to activate the MAPK pathway (Figure 4A). These data suggest that AM is involved in the activation of the MAPK pathway through AMR.

The activation of the MAPK pathway by AM in CAFs suggests that AM may be involved in CAFs growth through an autocrine/paracrine loop. All the CAFs showed no increase in proliferation in the presence of the maximum AM concentrations (10^{-7} M) when compared with untreated cells after 6 days treatment (Figure 4B). Consistent with an autocrine function for AM in these cells, α AM- or α AMRs-added to CAFs culture medium significantly reduced cell proliferation by as much as 40% ($p < 0.01$) when compared with cells treated with a nonspecific isotype control antibody (Figure 4B). Taken together, these observations indicate that AM is involved in the CAFs growth through AMR.

AM secreted by CAFs contributes to the angiogenesis into *in vivo* Matrigel plug bioassays

We hypothesized that AM as CAFs-derived factor might be involved in the angiogenic activities of growing tumors. To this end, we used the *in vivo* Matrigel plug bioassays to assess angiogenesis in response to AM released by CAF3 in a non-inflammatory setting. Mice

were injected subcutaneously (s.c.) anterior to the abdominal rectus sheath with Matrigel alone or with Matrigel admixed to CAF3, or admixed to NHDFs. *In vivo* Matrigel plug bioassays for angiogenesis revealed that plugs injected with CAF3 (Figure 5A, e, f) were significantly more vascularized than did plugs injected with NHDFs (Figure 5A, b, c) or without fibroblasts (not shown). Similar results were obtained with CAF1, CAF2, CAF6 and CAF8 (not shown). Importantly, these results demonstrate that CAFs are not only critical for the recruitment of vascular cells such as vascular and lymphatic endothelial cells and pericytes to enhance angiogenesis and lymphangiogenesis, but also that they can directly mediate these effects in the absence of tumor cells. Therefore, we hypothesized that AM secreted by CAF3 might be involved in the vascularization that occurred in the *in vivo* Matrigel plug bioassays injected with CAF3.

To demonstrate that AM secreted by CAF3 is involved in the promotion of the vascular and lymphatic channels, we used treatment with α AMRs to inhibit recruitment of circulating AMR-positive cells as reported previously [25]. Matrigel plugs supplemented with CAF3 were injected s.c. into C57BL/6 mice forming semisolid plugs. Twenty-four hours later, mice were treated by intraperitoneal (i.p.) injection with α AMRs or control IgG at 350 μ g every three days for a total of 15 days. Treatment of the animals with α AMRs induced a clear decrease of the angiogenesis and lymphangiogenesis in the plugs injected with CAF3 (Figure 5A, h, i). No effect on the vascular and lymphatic channels can be observed in the plugs of group animals treated with control IgG (Figure 5A, k, l). Quantification of CD31-positive endothelial cells (Figure 5B) and LYVE-1 positive lymphatic endothelial cells (Figure 5C) demonstrated a marked decrease in the number of both cell types in plugs admixed with CAF3 from animals treated with α AMR compared to animals that received control IgG ($p < 0.001$; Figures 5A, 5B, and 5C). In second series of experiments, *in vivo* Matrigel plug bioassays for angiogenesis was quantitated by measuring the uptake of FITC-dextran (~150,000) into plugs before their removal from mice. The data demonstrate that the vascularization induced by the CAF3 injected into the plugs was stable and functional (Figure 5D). α AMRs treatment significantly inhibited by 60% to 75% the uptake of FITC-dextran in plugs compared to the plugs from animal treated with rabbit control IgG (Figure 5D). These data suggest that a part of angiogenesis and lymphangiogenesis revealed in plugs is due to AM secreted by CAF3.

To strengthen our findings, we therefore tested the possibility that AM secreted by CAFs might be involved into the recruitment of endothelial cells and pericytes to foster a functional and stabilized angiogenesis. We had shown that AM induces recruitment of different cell types such as endothelial-like cells, pericytes, and macrophages/

monocytes in an *in vivo* Matrigel plug bioassays [25]. AM receptors are expressed in cultured primary HUVECs [38] and HUVSMCs [23], suggesting that these cells could be recruited by AM secreted by CAFs to assist neovessels formation during tumor growth. The migration and invasion assays demonstrate that CAF3-conditioned medium (CAF3-CM) promoted invasion of bone marrow-derived cells (BMDCs), migration and invasion of HUVECs and HUVSMCs in Transwell assay (Figures 6A, 6B, and 6C). Neutralization of CAF3-CM with a function-blocking antibody to AM (α AM) or pre-incubation of

cells with α AMRs significantly inhibited the stimulating effects of CAF3-CM on migration and invasion (Figures 6A, 6B, and 6C). These data strongly suggest that AM must be one of the CAF-derived factors responsible for endothelial cells, pericytes/smooth-muscle cells and BMDCs recruitment to promote a stabilized and functional angiogenesis. Importantly, *in vivo* Matrigel plug bioassays for angiogenesis revealed that plugs injected with CAF3 were significantly vascularized than did plugs injected with a human breast cancer cell line MCF-7 which express low basal levels of AM mRNA (Figures 7A, 7B, and 7C).




Figure 4: Effect of AM and AM signaling blockade on growth of CAFs *in vitro*. **A.** intracellular-signaling pathway induced by AM in CAFs. CAFs were treated with AM (10^{-7} M) for the indicated amounts of time in minutes and then immunoblotted for pERK1/2 and ERK1/2. MEK inhibitor (U0126) inhibited AM induced phosphorylation of ERK (10 μ M, 30 min). EGF was used as a positive control to stimulate the phosphorylation of ERK1/2. AM-induced phosphorylation of ERK1/2 is inhibited upon pre-incubation of CAFs with α AMRs for 30 min. β -GAPDH was used as a loading control. **B.** AM system blockade inhibits CAFs growth *in vitro*. Cells were seeded at a density of 2×10^3 cells per well in 24 multiwell plates in the presence of medium containing 2% FBS. Cells were treated for 6 days with AM (10^{-7} M), α AM (70 μ g/ml), α AMRs (70 μ g/ml), or control IgG (70 μ g/ml). For each treatment, six wells were prepared for MTT assay. Each *bar* represents the mean \pm standard error of the mean of three independent experiments. Significant differences between the growth of cells treated with α AM, α AMRs, and that of untreated controls were determined by a one-way analysis of variance test (** $p < 0.01$; *** $p < 0.001$).

AM blockade inhibits the growth of MCF-7 cells/CAF3- tumor xenografts *in vivo*

To assess the role of AM in CAFs function, we adopted a well-established bioassay, involving co-inoculation with transformed epithelial cells into a heterotopic site, where the effects of myfibroblasts on tumor growth could be assessed [6, 11]. We choose the MCF7 cells since they express barely detectable levels of AM mRNA (Figure 8A) and ir-AM (< 6 pg/mg protein) to evaluate better the role of AM expressed by the myfibroblasts in tumor growth *in vivo* when CAFs and MCF7 cells are co-injected to nude mice. Interestingly, MCF7 cells express AMR suggesting that it might be sensitive to AM (Figure 8A). In fact, treatment of MCF7

cells with AM led to phosphorylation of ERK1/2 that was observed after 20 min of treatment (Figure 8B). Inhibition of MEK with U0126 (10 μ M for 30 min) prevented the stimulatory effect of AM on pERK1/2 (Figure 8B). These data suggest that AM could be one of the factors secreted by tumor microenvironment to cross talk with breast cancer cells *in vivo*.

To investigate the role of AM expressed by CAFs in tumor growth of breast cancer cells *in vivo*, MCF-7 cells were injected s.c. in immunodeficient mice either alone, or admixed with CAF3. Tumors co-injected with CAF3 grew significantly faster and were larger than tumors in mice injected only with MCF-7 cells (Figure 9A) indicating a potent increased tumor cell proliferation in the presence of CAF3. We hypothesized that breast CAFs might




Figure 5: α AMR inhibit the angiogenesis and lymphangiogenesis induced-CAFs in an *in vivo* Matrigel plug bioassay. A. C57BL/6 mice were injected s.c. at the abdominal midline with 0.4 ml of growth factor-depleted Matrigel admixed to NHDFs (1.5×10^6 cells) (a, b, and c) or to CAFs (1.5×10^6 cells) (d, e, and f). α AMRs (g, h, and i) or control IgG (j, k, and l) was administered i.p. to C57BL/6 mice with Matrigel admixed to CAFs every three days, starting 24h after Matrigel injection, for 15 days. Matrigel plugs were isolated and fixed with formalin, embedded, and sectioned for immunohistochemical. Microphotographs of histochemical-stained Matrigel sections for H&E are shown (a, d, and g). Staining of blood vessels with anti-CD31 antibody (b, e, and h) and lymphatic vessels with anti-LYVE-1 antibody (c, f, and i) of the Matrigel plugs admixed with NHDFs or CAFs is shown. Panels are representative of multiple fields from five or six plugs per group. Scale bar, 50 μ m. B & C. quantitative assessment of the density of cells that stained positive for CD31 (B), or LYVE-1 (C) was conducted for the entire surface of the corresponding slides using CALOPIX Software. MBF_Image J 1.43U software was used for the analysis. The values shown represent the means \pm standard error of the mean (***) $p < 0.001$. D. after 15 days of treatment of three independent groups, mice were injected i.v. with FITC-dextran (150, 000); Matrigel plugs were removed, and the volume of new blood vessels was assessed by measurement of intravascular FITC-dextran content (normalized to FITC-dextran in the circulating plasma). Values are averages \pm SE of six animals (***) $p < 0.001$.




Figure 6: Effect of AM signaling blockade on CAF3-CM induced migration and invasion of cells *in vitro*. A, B & C. CAF3-CM regulates migration and invasion of HUVECs and HUVSMCs and invasion of BMDCs *in vitro*. The bottom wells of all chambers were filled with CAF3-CM and the control well was filled with DMEM containing 2% FBS (control). To neutralize the ir-AM secreted in the CAF3-CM, it was pretreated for 30 minutes with α AM (70 μ g/ml). Bone Marrow cells (A, 5×10^5 cells), HUVECs (B, 3×10^4 cells), or HUVSMCs (C, 3×10^4 cells) pretreated for 30 min with 23 μ g/ml each of α CLR, α RAMP2 and α RAMP3 (α AMRs), or control IgG (70 μ g/ml) were placed in the upper chamber and incubated as described in the Materials and Methods. The cells that migrated were stained with DAPI and counted at 50x magnification using a microscope. Data are expressed as the number of migrated cells in 10 high-power fields, and the values represent the mean \pm SEM of three independent experiments, each performed in triplicate. The asterisk (*) is used for comparison to control cells (** $p < 0.01$; *** $p < 0.001$) and the plus symbol (+) is used in comparison to CM-treated cells (++) $p < 0.01$; (+++) $p < 0.001$.




Figure 7: MCF-7 cells showed barely detectable angiogenesis compared to CAFs in an *in vivo* Matrigel plug bioassay. **A.** Expression of AM mRNA in MCF-7 cells and CAF3. Total RNA (1 μ g, DNA-free) prepared from MCF-7 cells and CAF3 was transcribed into cDNA and subjected to RT-qPCR as described in the Figure 3A (** $p < 0.001$). **B.** C57BL/6 mice were injected s.c. at the abdominal midline with 0.4 ml of growth factor-depleted Matrigel admixed to MCF-7 (1.5×10^6 cells) or to CAFs (1.5×10^6 cells) for 15 days. Matrigel plugs were processed as described in Figure 5. Staining of blood vessels with anti-CD31 antibody of the Matrigel plugs admixed with MCF-7 cells or CAFs is shown. Panels are representative of multiple fields from five or six plugs per group. Scale bar, 50 μ m. **C.** quantitative assessment of the density of cells that stained positive for CD31 was conducted for the entire surface of the corresponding slides using CALOPIX Software. MBF_Image J 1.43U software was used for the analysis. The values shown represent the means \pm standard error of the mean (** $p < 0.001$).

support tumor growth in part through the stimulation of angiogenesis, via the secretion of AM. Interestingly, the tumors in mice co-injected with NHDFs had a phenotype not different from the one obtained with the MCF-7 alone (Figure 9A).

Remarkably, the co-inoculated CAF3 survived in large numbers in tumors together with carcinoma cells for periods of up to 29 weeks after injection, as determined by immunohistochemistry using an antibody specific for human vimentin (Figure 9B) and α -SMA (Figure 9B), which MCF-7 cells fail to express. It is of interest to observe that CAF3 demonstrates expression of AM in

xenografts *in vivo* (Figure 9C, arrows) which demonstrates that CAF3 maintained the expression of AM *in vitro* as well as *in vivo*.

To evaluate the functional role of AM in MCF-7/CAF3 xenografts growth, we investigated the effects of inhibition of AM signaling on tumor xenografts. To assess the potential therapeutic value of α AMRs and AM antagonist (AM_{22-52}), athymic nude mice bearing established MCF-7/CAF3 xenografts ($\sim 200 \text{ mm}^3$) were treated with α AMRs, AM_{22-52} , or control IgG. Treatment was administered by i.p daily injection for AM_{22-52} (50 $\mu\text{g}/\text{mouse}$), and every 3 days for α AMRs (12 mg/kg) and




Figure 8: MAPK pathway is activated by AM in MCF7 cells. **A.** expression of AM, CLR, RAMP2, and RAMP3 mRNAs in MCF7 cells. Total RNA (1 μg , DNA-free) prepared from MCF7 cells was transcribed into cDNA and subjected to real-time quantitative reverse transcriptase-polymerase chain reaction for the estimation of the relative ratios of AM, CLR, RAMP2, and RAMP3 mRNAs to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA. Each bar depicts the mean \pm standard error of the mean of the three independent experiments from three independent preparations of total RNA from MCF7 cells. **B.** intracellular-signaling pathway induced by AM in MCF7 cells. MCF cells were treated with AM (10^{-7} M) for the indicated amounts of time in minutes and then immunoblotted for pERK1/2 and ERK1/2. MEK inhibitor (U0126) inhibited AM induced phosphorylation of ERK (10 μM , 30 min). EGF was used as a positive control to stimulate the phosphorylation of ERK1/2. β -GAPDH was used as a loading control.

control IgG (12 mg/kg) as reported previously [23, 24]. To monitor tumor growth, tumor volume was measured throughout the treatment period. The growth of the MCF-7/CAF3 xenografts was significantly reduced by α AMRs and AM₂₂₋₅₂ treatments compared with that in the control group (Figure 9D). After 12 weeks treatment period, animals were sacrificed, and tumor size was assessed. The mean tumor weights in the animals treated with control IgG, α AMRs, and AM₂₂₋₅₂ were 2.5 ± 0.4 g, 0.4 ± 0.10 g, and 0.5 ± 0.15 g, respectively (Figure 9E).

AM blockade impairs tumor angiogenesis and induces apoptosis

Immunohistochemical staining performed on the tumor xenografts demonstrated significant differences

in the Ki-67 labeling index between the animals treated with α AMRs, AM₂₂₋₅₂, and control IgG (Figures 10A and 10B). Significantly higher numbers of cleaved caspase-3-positive cells were observed in tumors from the animals treated with α AMRs and AM₂₂₋₅₂ (Figures 10A and 10C). MCF-7/CAF3 xenografts from IgG-control-treated animals were significantly more vascularized, as assessed by immunostaining for the endothelial cell marker CD31 (Figure 10A). Consistent with our hypothesis that AM signaling inhibition would result in a decrease in angiogenesis, immunohistochemical staining for CD31 demonstrated that tumor vascularization is deeply disrupted in tumors from animals treated with α AMRs and AM₂₂₋₅₂ (Figure 10A). Quantification of CD31-positive endothelial cells demonstrated a clear decrease in tumors from animals treated with α AMRs and AM₂₂₋₅₂




Figure 9: Enhanced tumor growth kinetics of MCF-7 breast cancer cells comingled with CAF3. A. MCF-7 cells (1×10^6 cells) were injected alone or coinjected with myfibroblasts (CAF3) (3×10^6 cells) subcutaneously into nude mice. Tumor volume was plotted in indicated days (** $p < 0.01$; *** $p < 0.001$). B & C. MCF-7 cells/CAF3 xenograft sections were immunostained with anti- α -SMA and anti-vimentin (B) with a merged view shown, or anti-AM and anti- α -SMA antibodies (C). AM⁺ α -SMA⁺ myfibroblasts are shown in a merged view (C, arrows). Scale bar, 50 μ M. D. AM signaling blockade inhibited the growth of MCF-7 cells/CAF3 xenografts *in vivo*. MCF-7 cells (1×10^6 cells) admixed to CAF3 (3×10^6 cells) were injected subcutaneously into the flanks of athymic nude mice (6 weeks old) ($n = 10$ in each group). Mice with tumor volume averaging ~ 200 mm³ received i.p. injections of α AMRs (12 mg/kg) every 3 days or AM₂₂₋₅₂ peptide (50 μ g/mouse) daily. Control mice were treated with 12 mg/kg of nonspecific isotype control IgG. Tumor size was measured every 3 days, and significant differences between the animals treated with α AMRs and AM₂₂₋₅₂ and those treated with control IgG were determined by a one-way analysis of variance test (** $p < 0.01$; *** $p < 0.001$). E. tumors were weighed immediately after excision and the average tumor weight is indicated as the mean \pm SEM ($n = 10$).

compared with the levels in control tumors (Figures 10A and 10D).

DISCUSSION

CAFs, myofibroblast-rich cell populations extracted from human carcinomas maintain an ability to promote tumorigenesis. These cells, passaged for 10 passages doubling *in vitro* without ongoing interaction with carcinoma cells, retained their ability to promote tumor growth when co-injected with carcinoma cells into immunodeficient mice [39, 40]. However, the molecular mechanisms underlying their tumor-promoting ability are poorly understood. Some have reported the

importance of somatic genetic alterations in forming the tumor-promoting stroma, yet their existence remains controversial [41–43].

In the present experiments, we show that (i) The CAFs exhibit increased α -SMA expression that is indicative of myofibroblasts. (ii) Immunofluorescence with macrophages markers CD68, CD163 and F4/80 revealed that CD68 was also cross-reactive but with less intensity in fibroblasts as reported previously [33]. Both antibodies against monocytes/macrophage markers, F4/80 and CD163 do not stained CAFs populations, ruling out the presence of macrophages and identified the isolated cells as cancer-associated fibroblasts (CAFs). (iii) Myofibroblasts produce increased levels of AM mRNA as




Figure 10: AM blockade induces apoptosis and impairs angiogenesis in MCF-7/CAFs tumor xenografts. A. representative images of tumors from the animals treated with control IgG, α AMRs, and AM₂₂₋₅₂. Tumor sections were stained with H&E, Ki-67, cleaved caspase-3, and CD31. Cleaved caspase-3- and Ki-67-positive cells are shown; they were analyzed on the basis of 10 magnification fields (400x) per section. Immunohistochemical staining of the endothelial cell surface marker CD31 was used to determine the microvessel density. Quantitative assessment of the density of cells that stained positive for Ki-67 B. cleaved caspase-3 C. or CD31 D. was conducted for the entire surface of the corresponding slides using CALOPIX Software. MBF_Image J 1.43U software was used for analysis. The values shown represent the mean \pm SEM (** $p < 0.01$; *** $p < 0.001$).

well as ir-AM when compared to normal fibroblasts. (iv) α AM and α AMR could inhibit the basal levels of CAFs proliferation *in vitro*, which is consistent with the fact that AM can act in an autocrine/paracrine manner to induce CAFs proliferation and increases activation of the MAPK pathway. The presence of an autocrine loop suggests that the foci of AM-producing cells in tumor tissue could stimulate cells expressing AM receptors through autocrine/paracrine mechanisms. (v) Myofibroblasts extracted from within invasive human breast cancer masses are more competent than normal fibroblasts in enhancing a stable vascularization in *in vivo* Matrigel plug bioassay for angiogenesis. (vi) ir-AM secreted by the myofibroblasts is responsible of induction of migration and invasion of endothelial cells, pericytes, and BMDCs *in vitro* and *in vivo*, thereby boosting tumor angiogenesis. (vii) We demonstrated that some CAFs cultures expressed both AM and SDF-1 mRNAs. It will be of interest to understand whether AM and SDF-1 peptides act in concert or separately to promote tumor growth when both are relatively well expressed in CAFs.

We demonstrated that CAFs admixed with breast cancer cells, enhanced angiogenesis both in heterotopic MCF-7 tumors and in an *in vivo* Matrigel plug bioassay lacking cancer cells. The ability of CAFs to influence tumor growth was partly dependent on their ability to induce angiogenesis by CAF-derived AM and recruitment of BMDCs. On the basis of results from our study as well as those from previous report [44], we conclude that AM is an angiogenic and tumor promoting factor that is secreted by tumor cells and stromal cells such as myofibroblasts in breast cancer tumors.

The blockade of the AM receptors by systemic administration of α AMRs or AM₂₂₋₅₂ inhibits angiogenesis in an *in vivo* model and the growth of admixed MCF-7 cells/CAF3 xenografts. We demonstrated that addition of CAF3 to Matrigel plug bioassay *in vivo* significantly enhanced plug neovascularization, which was effectively inhibited by systemic injection of α AMRs. This blocking effect was confirmed on tumor xenografts growth *in vivo*. In fact, the treatment of admixed MCF-7 cells/CAF3 xenograft-bearing mice with α AMRs or AM₂₂₋₅₂ consistently resulted in tumor regression, suggesting that the tumor is most susceptible to α AMRs and AM₂₂₋₅₂ therapies. CAF3-treated with α AM or α AMRs showed a growth inhibition *in vitro* suggesting that the growth inhibition *in vivo* might be due to the effect of α AMRs and AM₂₂₋₅₂ on tumor vasculature and CAFs growth *in vivo*. The immunohistochemical analysis of admixed tumors xenografts derived from animals treated with α AMRs or AM₂₂₋₅₂ showed a clear decrease in microvessel density, with a 65% to 80% reduction in endothelial cells and pericytes within the tumor, which is consistent with the role of AM in endothelial cell and pericyte survival and recruitment. Interestingly, the density of vessels with lumen decreased dramatically. The loss of microvessels

within α AMRs or AM₂₂₋₅₂-treated tumors suggests that AM stimulation of CLR/RAMP2/RAMP3-expressing tumor vasculature acts as a survival mechanism for proliferating tumor endothelium. In agreement with previous studies, these data demonstrate that AM secreted by CAFs could play a role to foster a stabilized and functional neovascularization in growing tumors [25, 38, 45]. Recently, we showed that the blockade of AM signaling selectively targets unstable tumor neovessels through rapid disengagement of the VE-cadherin/ β -catenin complex, destabilization of the cytoskeleton organization of endothelial cells, and subsequent apoptosis-mediated cell death [46].

The data reported in the present study echo findings of others demonstrating that stromal fibroblasts isolated from human prostate carcinomas have an increased ability to foster tumor formation when compared to normal prostatic fibroblasts [6]. In 1999, the groups of Tlsty and Cunha demonstrated a striking tumor-promoting property of stromal fibroblasts extracted from human prostate carcinomas when these were compared with control normal fibroblasts isolated from the noncancerous prostate gland [6]. Such fibroblasts have been shown to regulate carcinoma cell growth, differentiation, and tumorigenesis, either in a positive or negative fashion [47–49].

CAF3 exhibit increased levels of secretory molecules that include growth factors and chemokines such as VEGFA, HGF, PDGF, TNF, IL-6, IL-8 and SDF-1 [for review see ref 50]. CAFs have been shown to promote tumor growth by directly stimulating tumor cell proliferation and by enhancing angiogenesis [3, 10, 11]. Fibroblasts are also key players in wound healing [51, 52], mediating extracellular matrix remodeling and generation of contractile forces. It has also been suggested that fibroblasts mediate the transition from acute to chronic inflammation by inappropriately providing recruitment, survival, and retention signals to infiltrating leucocytes, thus inhibiting the normal resolution of inflammation [53–55]. Previous studies have reported that fibroblasts are a source of cytokines or chemokines or both in tumors [56–58]. Moreover, a study-using laser capture microdissection revealed CXCL12 and CXCL14 to be upregulated in stroma of prostate and basal cell carcinomas [59, 60]. The ability of CAFs to influence tumor growth was partly dependent on their ability to induce angiogenesis by CAF-derived SDF-1 (also known as CXCL12) and recruitment of bone marrow-derived endothelial cells [11] or by CAF-derived PDGF-C, a member of the PDGF family [12] or secreting proangiogenic factors [61].

The notion of targeting CAFs to inhibit tumor growth and progression is attractive due to the increasing identification of stimulatory factors derived from the tumor stroma. Targeting of stromal fibroblast effector functions by drugs inhibiting the action of osteopontin, CXCL12, CXCL14, FGF-2, PDGF-C, AM, and many more, singularly or in combination, holds promise of

producing therapeutic efficacy. In addition, approaches to prevent the recruitment and phenotypic conversion of CAFs are highly warranted.

MATERIALS AND METHODS

Cell culture

The human breast cancer cell line MCF7 and the partially differentiated monocyte-macrophage cell line RAW 264.7 were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). The cells were grown in a humidified atmosphere at 37°C and 5% CO₂ in DMEM (Lonza BioWhitaker, France) supplemented with L-glutamine (2 mM) and 5% heat-inactivated fetal calf serum (FCS) (Lonza) and in absence of antibiotics. HUVECs and HUVSMCs (Lonza) were cultured in EGM-2 medium (Lonza) containing 2% FBS and M199 medium (Invitrogen Life Technologies Inc.) containing 20% FBS, respectively, in humidified atmosphere at 37°C with air/5% CO₂. HUVECs and HUVSMCs monolayers from passages 2–4 were used in these studies.

Isolation and culture of cancer-associated fibroblasts

Cancer-associated fibroblasts (CAFs) were isolated from human breast tumor biopsies as previously described [62]. Tissues were digested with F15 medium with 0.037% hyaluronidase (sigma), 1 mg/ml collagenase/dispase (Roche), 1% FBS, and antibiotics for 1-2 hr at 37°C. Dissociated cells were filtered through both 100 µm and 40 µm filters. Washed filtrates were plated onto 1% gelatin-coated plates and cultured in 10% FBS-containing DMEM/F12 medium maintained at 37°C in a humid atmosphere of 95% air/ 5% CO₂. After 48 hours incubation, suspension tumor cells were removed after vigorous washing. After 2-3 passages, an apparently pure fibroblast population was obtained. All CAFs used in this study had undergone fewer than ten population doublings in culture. Normal human dermal fibroblasts (NHDFs) (Promocell) were cultured in promocell growth medium (Promocell).

Immunostaining of the human fibroblasts

Primary cultured fibroblasts were examined by immunofluorescence using anti-cytokeratin-18 (Sigma), human specific anti-vimentin (V9; Novocastra laboratories, Ltd., UK), anti-fibroblast surface protein (1B10; Sigma), anti-human CD31 (Santa Cruz, California), anti- α -SMA (1A4; Dako, Denmark), anti-PDGFR α (Dako), anti-human CD68 (1/100, BD Pharmingen™), anti-human CD163 (1/100, Bio-Rad), and anti-human F4/80 (1/50, Invitrogen) antibodies. The antibodies anti-AM, anti-

CLR, anti-RAMP2, and anti-RAMP3 were developed and characterized in the laboratory.

Immunoassay for human AM

CAFs (1.5×10^6) and NHDFs (1.5×10^6) were cultured in DMEM/F12 medium for 48 hours. The immunoreactive AM in cell extracts as well as in medium was measured using a commercially available AM ELISA kit (Euromedex, Strasbourg, France).

RNA preparation and real-time quantitative RT-PCR

Total RNA was prepared from CAFs, NHDFs, and MCF-7 cells and reverse transcribed to cDNA as described [63]. Human AM, CLR, RAMP2, RAMP3 and GAPDH mRNAs [58] and human stromal-derived factor (SDF1) mRNA (forward primer 5'-CGATTCTTCGAAAGCCAATGT-3' and reverse primer 5'-CTTGCTTGTTGTTGTTCTTCAGC-3') were amplified, detected and quantitated in real-time using LC480 PCR system (Roche Diagnostics, Meylan, France) as described [63, 64].

Western blot analysis

Cell extracts were prepared and immunoblotted for phospho-ERK1/2, and ERK1/2 using the MAPK-phospho-ERK1/2 pathway sampler kit (Cell signaling Technology, Inc.) as previously described [23]. Antibody signals were revealed using an enhanced chemiluminescence kit (ECL kit, Invitrogen Life Technologies Inc.).

Cell proliferation assay

AM (10^{-7} M), rabbit anti-human AM (α AM; 70 µg/ml), and anti-human AM receptor (α CLR, α RAMP2 and α RAMP3) (70 µg/ml) neutralizing antibodies (purified IgG) previously developed in house [21, 38] were added daily to the culture to evaluate their effects on cell proliferation. After six days treatment, the effects were examined by 3-(4, 5-dimethylthiazol-2, 5-diphenyltetrazolium bromide) (MTT) assay (Promega, Lyon, France).

Transwell migration and invasion assays

A modified Boyden chamber assay was used to analyze migration and chemoinvasion of murine bone marrow derived cells (BMDCs), HUVECs, or HUVSMCs as described previously [38, 64].

In vivo Matrigel plugs studies and analysis

Female C57BL/6 mice were injected s.c. above the rectus abdominus with 600 µl of Matrigel (Becton-

Dickinson, Le Pont de Claix, France), admixed to NHDFs (1.5×10^6) or CAFs (1.5×10^6) in 50 μ l of PBS or alone as a negative control. Twenty-four hours later, mice injected with Matrigel combined with CAFs were randomized into two groups and treated i.p. with α AMRs (330 μ g) or preimmune serum (purified IgG, 330 μ g) every three days. Two weeks later, animals were sacrificed, and the Matrigel plugs were dissected and fixed in 4% paraformaldehyde (PFA) for histological analysis. Immunohistochemical analysis was performed on paraffin-embedded sections using the Vectastain Elite ABC Universal kit (Vector Laboratories, Burlingame, CA) with antibodies from Dako Inc. (Glostrup, Denmark) for CD31 (1:20) and LYVE-1 (1:100).

The second group of animals was injected systemically into the lateral tail vein with 100 mg/kg FITC-dextran solution (molecular weight $\sim 150,000$; Sigma Chemical Co., Lyon, France) and allowed to circulate for 25-30 min. Before mice sacrifice, blood samples were collected by cardiac puncture and plasma was separated. The Matrigel plugs were resected, placed into tubes containing Dispase reagent (Thermo-Fisher, Cergy-Pontoise, France), and homogenized. After centrifugation, the supernatant was saved for analysis of fluorescence. Fluorescence readings were obtained on an FL600 fluorescence plate reader (BioTek). Angiogenic response was expressed as a ratio of Matrigel plug fluorescence/plasma fluorescence.

***In vivo* tumor growth assessment**

MCF-7 cells (1×10^6) alone ($n = 10$) or admixed with CAFs (3×10^6) ($n = 30$) were injected subcutaneously into the right flank of female nude mice. Tumors sizes were determined with a dial-caliper measurements, and the tumor volume was calculated as width \times length \times height $\times 0.5236$ (for ellipsoid form). Mice with tumor volume greater than 2,000 mm³ were sacrificed in accordance with Aix-Marseille University Animal Rights Committee guidelines. When the tumors were ~ 200 mm³ in size, animals were randomly divided into three groups. One group ($n = 10$) received intraperitoneal (i.p.) injection of α AMRs (12 mg/kg purified IgG in 200 μ l PBS) every 3 days; the second group ($n = 10$) received 50 μ g of AM antagonist AM₂₂₋₅₂ daily as described previously [24]; and the third group ($n = 10$) received an irrelevant antibody (IgG of the same isotype). The α AMRs were characterized as described [25] and all IgG preparations were tested for endotoxin using the Pyrogen plus Limulus ameboyecote lysate kit (Lonza). All antibody preparations used in animal studies contained < 1.25 U/ml endotoxin. Tumors sizes were measured every 3 days, and mice were sacrificed at 29 weeks after injection. Tumors were embedded in Paraffin for pathologic studies and immunohistochemistry.

Immunohistochemical staining

Sections (6 μ m) were cut from formalin-fixed paraffin-embedded xenografts. Immunohistochemistry was performed using the Vectastain Elite ABC Universal kit (Vector Laboratories, Burlingame, CA) as described previously [23, 64]. Antibodies against CD31 (1:20, Dianova), Ki-67 nuclear antigen (1:100; Dako), and cleaved caspase-3 (1:100; BD Pharmingen™) were used for the analysis. For each marker, whole-surface staining was quantified using Image J Software (NIH, Bethesda, USA).

Tumor vascular density

Quantitation of vessel count was performed as previously described [65]. The blood vessels were counted randomly from non-necrotic areas in each tumor section in an x200 microscope field, on CD31-stained tissue sections.

Statistical analysis

Data are expressed as means \pm SEM from at least three independent experiments. One-way analysis of variance (ANOVA) or Fisher's PLSD test (Statview 512; Brain Power Inc., Calabasas, CA, USA) was used for statistical analysis. Differences were considered significant at values of $p < 0.05$.

ACKNOWLEDGMENTS

The authors thank V. GAGNA for her excellent secretarial assistance. This study was supported by grants from Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique Hôpitaux de Marseille (AP-HM), ARTC Sud, and SIRIC (grant INCa-DGOS-Inserm 6080). The ARTC Sud financially supported Zohra Benyahia.

CONFLICTS OF INTEREST

The authors have no potential conflicts of interest to disclose.

REFERENCES

1. Bissell MJ, Radisky D. Putting tumours in context. *Nat Rev Cancer*. 2001; 1: 46-54.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011; 144:646-674.
3. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG, Moses HL. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. *Science*. 2004; 303: 848-851.
4. Coussens LM, Werb Z. Inflammation and cancer. *Nature*. 2002; 420: 860-867.

5. Jacobs TW, Byrne C, Colditz G, Connolly JL, Schnitt SJ. Radial scars in benign breast-biopsy specimens and the risk of breast cancer. *N Engl J Med.* 1999; 340: 430-436.
6. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. *Cancer Res.* 1999; 59: 5002-5011.
7. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. *Nature.* 2004; 432:332-337.
8. Kalluri R, Zeisberg M. Fibroblasts in cancer. *Nat Rev Cancer.* 2006; 6:392-401.
9. Trimboli AJ, Cantemir-Stone CZ, Li F, Wallace JA, Merchant A, Creasap N, Thompson JC, Caserta E, Wang H, Chong JL, Naidu S, Wei G, Sharma SM, et al. Pten in stromal fibroblasts suppresses mammary epithelial tumours. *Nature.* 2009; 461:1084-1091.
10. Allinen M, Beroukhi R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, Schnitt S, Sellers WR, Polyak K. Molecular characterization of the tumor microenvironment in breast cancer. *Cancer Cell.* 2004; 6: 17-32.
11. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. *Cell.* 2005; 121: 335-348.
12. Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, Zaminker J, Ferrara N. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. *Cancer Cell.* 2009; 15: 21-34.
13. Desmouliere A, Guyot C, Gabbiani G. The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. *Int J Dev Biol.* 2004; 48:509-517.
14. Sugimoto H, Mundel TM, Kieran MW, Kalluri R. Identification of fibroblast heterogeneity in the tumor microenvironment. *Cancer Biol Ther.* 2006; 5:1640-1646.
15. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. *Nature.* 1998; 393: 333-339.
16. Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, Muff R, Fischer JA, Foord SM. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. *Pharmacol Rev.* 2002; 54: 233-246.
17. Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. *Endocr Rev.* 2000; 21:138-167.
18. Lopez J, Martinez, A. Cell and molecular biology of the multifunctional peptide, adrenomedullin. *Int Rev Cytol.* 2002; 221, 1-92.
19. Zudaire E, Martinez A, Cuttitta F. Adrenomedullin and cancer. *Regul Pept.* 2003; 112: 175-183.
20. Miller MJ, Martínez A, Unsworth EJ, Thiele CJ, Moody TW, Elsasser T, Cuttitta F. Adrenomedullin expression in human tumor cell lines. Its potential role as an autocrine growth factor. *J Biol Chem.* 1996; 271: 23345-23351.
21. Ouafik L, Sauze S, Boudouresque F, Chinot O, Delfino C, Fina F, Vuaroqueaux V, Dussert C, Palmari J, Dufour H, Grisoli F, Casellas P, Brünner N, et al. Neutralization of adrenomedullin inhibits the growth of human glioblastoma cell lines *in vitro* and suppresses tumor xenograft growth *in vivo*. *Am J Pathol.* 2002; 160: 1279-1292.
22. Nouguerède E, Berenguer C, Garcia S, Bennani B, Delfino C, Nanni I, Dahan L, Gasmi M, Seitz JF, Martin PM, Ouafik L. Expression of adrenomedullin in human colorectal tumors and its role in cell growth and invasion *in vitro* and in xenograft growth *in vivo*. *Cancer Med.* 2013;2:196-207.
23. Berenguer-Daize C, Boudouresque F, Bastide C, Tounsi A, Benyahia Z, Acunzo J, Dussault N, Delfino C, Baeza N, Daniel L, Cayol M, Rossi D, El Battari A, et al. Adrenomedullin blockade suppresses growth of human hormone-independent prostate tumor xenograft in mice. *Clin Cancer Res.* 2013; 19: 6138-6150.
24. Ishikawa T, Chen J, Wang J, Okada F, Sugiyama T, Kobayashi T, Shindo M, Higashino F, Katoh H, Asaka M, Kondo T, Hosokawa M, Kobayashi M. Adrenomedullin antagonist suppresses *in vivo* growth of human pancreatic cancer cells in SCID mice by suppressing angiogenesis. *Oncogene.* 2003; 22: 1238-1242.
25. Kaafarani I, Fernandez-Sauze S, Berenguer C, Chinot O, Delfino C, Dussert C, Metellus P, Boudouresque F, Mabrouk K, Grisoli F, Figarella-Branger D, Martin PM, Ouafik L. Targeting adrenomedullin receptors with systemic delivery of neutralizing antibodies inhibits tumor angiogenesis and suppresses growth of human tumor xenografts in mice. *FASEB J.* 2009; 23: 3424-3435.
26. Ramachandran V, Arumugam T, Hwang RF, Greenson JK, Simeone DM, Logsdon CD. Adrenomedullin is expressed in pancreatic cancer and stimulates cell proliferation and invasion in an autocrine manner via the adrenomedullin receptor, ADMR. *Cancer Res.* 2007; 67: 2666-2675.
27. Zudaire E, Martinez A, Garayoa M, Pio R, Kaur G, Woolhiser MR, Metcalfe DD, Hook WA, Siraganian RP, Guise TA, Chirgwin JM, Cuttitta F. Adrenomedullin is a cross-talk molecule that regulates tumor and mast cell function during human carcinogenesis. *Am J Pathol.* 2006; 168:280-291.
28. Chen P, Huang Y, Bong R, Ding Y, Song N, Wang X, Song X, Luo Y. Tumor associated macrophages promote angiogenesis and melanoma growth via adrenomedullin in

- a paracrine and autocrine manner. *Clin Cancer Res.* 2011; 17:7230-7239.
29. Huang TH, Chu TH. Repression of miR-126 and upregulation of adrenomedullin in the stromal endothelium by cancer-stromal cross talks confers angiogenesis of cervical cancer. *Oncogene.* 2014; 33:3636-3647.
 30. Roszer T. Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. *Mediators of Inflammation.* 2015: 1-16.
 31. Bolling AN, Ovrevik J, Samulsen JT, Holme JA, Rakkestad KE, Mathisen GH, Paulsen RE, Korsnes MS, Becher R. Mono-2-ethylphthalate (MEHP) induces TNF- β release and macrophage differentiation through different signalling pathways in RAW264.7 cells. *Toxicology letters.* 2012; 209: 43-50.
 32. Kunz-Schughart LA, Weber A, Rehli M, Gottfried E, Brockhoff G, Krause SW, Andreesen R, Kreutz M. The classical macrophage marker CD68 is strongly expressed in primary human fibroblasts. [Article in German]. *Verh Dtsch Ges Pathol.* 2003; 87: 215-223.
 33. Inoue T, Plieth D, Venkov CD, Xu C, Neilson EG. Antibodies against macrophages that overlap in specificity with fibroblasts. *Kidney Int.* 2005; 67: 2488-2493.
 34. Serini G, Gabbiani G. Mechanisms of myofibroblast activity and phenotypic modulation. *Exp Cell Res.* 1999; 250: 273-283.
 35. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. *N Engl J Med.* 1986;315: 1650-1659.
 36. Kojima Y, Acar A, Eaton EN, Mellody KT, Scheel C, Ben-Porath I, Onder TT, Wang ZC, Richardson AL, Weinberg RA, Orimo A. Autocrine TGF- β and stromal cell-derived factor 1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. *Proc Natl Acad Sci USA.* 2010; 107: 20009-20014.
 37. Ilan N, Mahooti S, Madri JA. Distinct signal transduction pathways are utilized during the tube formation and survival phases of *in vitro* angiogenesis. *J Cell Sci.* 1998; 111: 3621-3631.
 38. Fernandez-Sauze S, Delfino C, Mabrouk K, Dussert C, Chinot O, Martin PM, Grisoli F, Ouafik L, Boudouresque F. Effects of adrenomedullin on endothelial cells in the multistep process of angiogenesis: involvement of CRLR/RAMP2 and CRLR/RAMP3 receptors. *Int J Cancer.* 2004; 108: 797-804.
 39. Mishra PJ, Mishra PJ, Humeniuk R, Medina DJ, Alexe G, Mesirov JP, Ganesan S, Glod JW, Banerjee D. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. *Cancer Res.* 2008;68:4331-4339.
 40. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. *Cell Cycle.* 2006; 5: 1597-601.
 41. Haviv I, Polyak K, Qiu W, Hu M, Campbell I. Origin of Carcinoma associated fibroblasts. *Cell Cycle.* 2009; 8:589-595.
 42. Weinberg RA. Coevolution in the tumor microenvironment. *Nat Gen.* 2008; 40:494-495.
 43. Polyak K, Haviv I, Campbell IG. Co-evolution of tumor cells and their microenvironment. *Trends Genet.* 2009; 25:30-38.
 44. Martinez A, Vos M, Guédez L, Kaur G, Chen Z, Garaoya M, Pío R, Moody T, Stetler-Stevenson WG, Kleinman HK, Cuttitta F. The effects of adrenomedullin overexpression in breast tumor cells. *J Nat Can Inst.* 2002; 94:1226-1237.
 45. Nikitenko LL, Fox SB, Kehoe S, Rees MC, Bicknell R. Adrenomedullin and tumor angiogenesis. *Br J Cancer.* 2006; 94:1-7.
 46. Khalfaoui-Bendriss G, Dussault N, Fernandez-Sauze S, Berenguer-Daizé C, Sigaud R, Delfino C, Cayol M, Metellus P, Chinot O, Mabrouk K, Martin PM, Ouafik L. Adrenomedullin blockade induces regression of tumor neovessels through interference with vascular endothelial-cadherin signalling. *Oncotarget.* 2015; 6:7536-7553. doi: 10.18632/oncotarget.3167.
 47. Kinzler KW, Vogelstein B. Landscaping the cancer terrain. *Science.* 1998; 280:1036-1037.
 48. Hayashi N, Cunha GR, Wong YC. Influence of male genital tract mesenchymes on differentiation of dunning prostatic adenocarcinoma. *Cancer Res.* 1990; 50:4747-4754.
 49. Picard O, Rolland Y, Poupon MF. Fibroblast-dependent tumorigenicity of cells in nude mice: implication for implantation of metastases. *Cancer Res.* 1986;46: 3290-3294.
 50. Kalluri R. The biology and function of fibroblasts in cancer. *Nat Rev Cancer.* 2016; 16: 582-598.
 51. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblast: one function, multiple origins. *Am J Pathol.* 2007; 170:1807-1816.
 52. Kisseleva T, Brenner DA. Mechanisms of fibrogenesis. *Exp Biol Med.* (Maywood). 2008; 233:109-122.
 53. Buckley CD, Pilling D, Lord JM, Akbar AN, Scheel-Toellner D, Salmon M. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. *Trends Immunol.* 2001; 22: 199-204.
 54. Smith RS, Smith TJ, Blieden TM, Phipps RP. Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. *Am J Pathol.* 1997; 151:317-322.
 55. Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB- Dependent Manner. *Cancer Cell.* 2010; 17:135-47.
 56. Gallagher PG, Bao Y, Prorock A, Zigrino P, Nischt R, Politi V, Mauch C, Dragulev B, Fox JW. Gene expression

- profiling reveals cross-talk between melanoma and fibroblasts: implications for host-tumor interactions in metastasis. *Cancer Res.* 2005; 65:4134-4146.
57. Mueller L, Goumas FA, Affeldt M, Sandtner S, Gehling UM, Brilloff S, Walter J, Karnatz N, Lamszus K, Rogiers X, Broering DC. Stromal fibroblasts in colorectal liver metastases originate from resident fibroblasts and generate an inflammatory microenvironment. *Am J Pathol.* 2007; 171:1608-1618.
58. Silzle T, Kreutz M, Dobler MA, Brockhoff G, Knuechel R, Kunz-Schughart LA. Tumor-associated fibroblasts recruit blood monocytes into tumor tissue. *Eur J Immunol.* 2003; 33:1311-1320.
59. Augsten M, Hägglöf C, Olsson E, Stolz C, Tsagozis P, Levchenko T, Frederick MJ, Borg A, Micke P, Egevad L, Ostman A. CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. *Proc Natl Acad Sci U S A.* 2009; 106:3414-3419.
60. Micke P, Kappert K, Ohshima M, Sundquist C, Scheidl S, Lindahl P, Heldin CH, Botling J, Ponten F, Ostman A. *In situ* identification of genes regulated specifically in fibroblasts of human basal cell carcinoma. *J Invest Dermatol.* 2007; 127:1516-1523.
61. Pietras K, Pahler J, Bergers G, Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. *PLoS Med.* 2008; 5: e19.
62. Israel N, Saez S. Relation between steroid receptor content and the response to hormone addition in isolated human breast cancer cells in short-term culture. *Cancer Res.* 1978; 38: 4314-4317.
63. Berenguer C, Boudouresque F, Dussert C, Daniel L, Muracciole X, Grino M, Rossi D, Mabrouk K, Figarella-Branger D, Martin PM, Ouafik L. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells. *Oncogene.* 2008; 27: 506-518.
64. Deville JL, Bartoli C, Berenguer C, Fernandez-Sauze S, Kaafarani I, Delfino C, Fina F, Salas S, Muracciole X, Mancini J, Lechevallier E, Martin PM, Figarella-Branger D, Ouafik L, Daniel L. Expression and role of adrenomedullin in renal tumors and value of its mRNA levels as prognostic factor in clear-cell renal carcinoma. *Int J Cancer.* 2009; 125: 2307-2315.
65. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. *N Engl J Med.* 1991; 324: 1-8.